Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada.

Robert C GrantColeman RotsteinGeoffrey LiuLeta ForbesKathy VuRoy LeePamela NgMonika KrzyzanowskaDavid WarrJennifer Knox

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)

Clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis. Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine. For regimens with low emetogenic risk, 5-HT3 antagonists are recommended over dexamethasone.

Keyphrases

chemotherapy induced
high dose
low dose
stem cell transplantation
breast cancer risk